The 19 most recent market catalysts affecting $NVS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 65
Dated September 17, CHMP Recommends EU Label Expansion For Novartis' Cosentyx In Polymyalgia Rheumatica After Inadequate Glucocorticoid Response Or Relapse During Taper
The CHMP's positive opinion for Cosentyx's label expansion into Polymyalgia Rheumatica (PMR) is a crucial development for Novartis. This recommendation, if followed by final approv…
Sep 17, 2026
Corporate Catalyst
Bearish
Impact 75
Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform
Novartis announced a mixed bag of news: the termination of its Phase 2 ALS drug trial for VHB937 due to efficacy failure, and the acquisition of Sironax's brain delivery platform f…
Sep 16, 2026
Corporate Catalyst
Bearish
Impact 75
'Novartis Experimental Drug for ALS Fails in Another Pipeline Hit' - Bloomberg
Novartis's experimental drug for ALS, a devastating neurological disease, failed in clinical trials. This is significant because it represents a setback for the company's pipeline,…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
HSBC Upgrades Novartis to Hold, Raises Price Target to $136
HSBC analyst Rajesh Kumar upgraded Novartis from a 'Reduce' to a 'Hold' rating, simultaneously raising the price target from $123 to $136. This change in analyst sentiment suggests…
Sep 10, 2026
Corporate Catalyst
Bearish
Impact 85
'Major Novartis shareholder calls for board shake-up after drug trial setbacks' - Reuters Exclusive Interview
This headline is a significant corporate catalyst for Novartis (NVS). A major shareholder demanding a board shake-up indicates deep dissatisfaction with current management and stra…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 95
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Novartis's announcement of the pelacarsen Phase III trial failure is a major negative catalyst. The drug's inability to meet its primary endpoint indicates a significant setback in…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. The global Phase III HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 did not meet its primary endpoint.
The failure of two Phase III trials for pelacarsen and del-desiran is a significant negative catalyst for Novartis. These drugs were considered important pipeline assets, with pela…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Market-Moving News for September 8th
Novartis's announcement of the pelacarsen Phase III trial failure is a significant negative catalyst, directly impacting its stock due to the loss of a potential blockbuster drug. …
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Novartis Reported Earlier, Its Phase III HARBOR Study Evaluating Del-Desiran In People Living With Myotonic Dystrophy Type 1 Did Not Meet Primary Endpoint
Novartis's failed Phase III HARBOR study for Del-Desiran in Myotonic Dystrophy Type 1 is a major setback, directly impacting the company's future revenue potential and R&D pipeline…
Sep 7, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, Royalty Pharma Announced An Update On Novartis’ Phase 3 Results From The Horizon Outcomes Trial For Pelacarsen, An Antisense Oligonucleotide Studied In Patients With Atherosclerotic Cardiovascular Disease And Elevated Lipoprotein(A)
The update on Novartis' Phase 3 results for Pelacarsen is a critical event for the pharmaceutical sector, particularly for companies involved in cardiovascular disease treatments. …
Sep 4, 2026
Corporate Catalyst
Bearish
Impact 85
Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint.
The failure of Novartis's pelacarsen Phase III trial is a significant negative catalyst for the company, as it represents a lost opportunity for a potentially blockbuster drug in t…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 85
Novartis shares are trading higher after the company announced topline results from its Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis.
The positive Phase III trial results for remibrutinib are a significant corporate catalyst for Novartis, directly impacting its stock positively due to the potential for a new, hig…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 85
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win
Novartis' remibrutinib achieved significant success in its Phase 3 trials for relapsing multiple sclerosis, demonstrating reduced relapse rates and a favorable safety profile. This…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto
Novartis' Pluvicto, a radioligand therapy, received FDA approval for an earlier stage of prostate cancer (mHSPC), nearly doubling its eligible patient pool. This is a significant p…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 85
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
Novartis' Q2 earnings significantly surpassed analyst expectations, driven by robust sales of its priority medicines like Kisqali and Kesimpta, effectively 'silencing generic fears…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 85
Novartis shares are trading higher after the company reported better-than-expected Q2 financial results
This headline is a significant corporate catalyst, directly impacting Novartis's share price due to strong financial performance. Better-than-expected earnings often signal effecti…
Jul 21, 2026
Corporate Catalyst
Bearish
Impact 92
Novartis Q2 Adj. EPS $2.41 Beats $2.13 Estimate, Sales $14.408B Beat $14.042B Estimate
Novartis announced its Q2 earnings, revealing adjusted EPS of $2.41, surpassing the $2.13 analyst consensus, and sales of $14.408 billion, exceeding the $14.042 billion estimate. T…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 75
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval
Novartis (NVS) has secured full FDA approval for its drug Fabhalta (iptacopan) for primary IgA nephropathy (IgAN), a significant milestone. This approval is based on Phase 3 trial …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.